[HTML][HTML] Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or …
…, R Goldwater, M Kankam, S Toubro, SB Nygård - Molecular …, 2023 - Elsevier
Objective Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide
greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from …
greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from …
[HTML][HTML] Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development
J Stenvang, I Kümler, SB Nygård, DH Smith… - Frontiers in …, 2013 - frontiersin.org
Cancer is a leading cause of mortality worldwide and matters are only set to worsen as its
incidence continues to rise. Traditional approaches to combat cancer include improved …
incidence continues to rise. Traditional approaches to combat cancer include improved …
[HTML][HTML] Topoisomerase-1 and-2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers
IMH Sønderstrup, SB Nygård, TS Poulsen… - Molecular Oncology, 2015 - Elsevier
Introduction Topoisomerase 1 (TOP1) and 2A (TOP2A) are potential predictive biomarkers
for irinotecan and anthracycline treatment, respectively, in colorectal cancer (CRC), and we …
for irinotecan and anthracycline treatment, respectively, in colorectal cancer (CRC), and we …
In Vitro CYP450 Enzyme Downregulation by GLP-1/Glucagon Coagonist Does Not Translate to Observed Drug-Drug Interactions in the Clinic
…, K Dahl, MH Friedrichsen, SB Nygård… - Drug Metabolism and …, 2022 - ASPET
NN1177 is a glucagon/glucagon-like peptide 1 receptor coagonist investigated for chronic
weight management and treatment of nonalcoholic steatohepatitis. Here, we show …
weight management and treatment of nonalcoholic steatohepatitis. Here, we show …
Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues
…, R Goldwater, M Kankam, S Toubro, SB Nygård - Medrxiv, 2022 - medrxiv.org
Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide greater weight
loss than agonists targeting the GLP-1 receptor alone. We report results from three phase 1 …
loss than agonists targeting the GLP-1 receptor alone. We report results from three phase 1 …
Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer
NF Jensen, DH Smith, SB Nygård… - Scandinavian journal …, 2012 - Taylor & Francis
The availability of systemic chemotherapy regimens for the treatment of patients with metastatic
colorectal cancer (mCRC) is based on the results from large prospective, randomized …
colorectal cancer (mCRC) is based on the results from large prospective, randomized …
The invariant chain CD74 protein is a cell surface binding partner of TIMP‐1 in breast cancer cells
…, A Bartels, EM Bech, SB Nygård… - Molecular …, 2023 - Wiley Online Library
Tissue inhibitor of metalloproteinases‐1 (TIMP‐1) regulates the proteolytic activity of matrix
metalloproteinases (MMPs), playing an important role in the homeostasis of the extracellular …
metalloproteinases (MMPs), playing an important role in the homeostasis of the extracellular …
[HTML][HTML] Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort
…, NF Jensen, B Markussen, MU Rømer, SB Nygård… - PloS one, 2013 - journals.plos.org
Background Topoisomerase I (Top1) is the target of Top1 inhibitor chemotherapy. The TOP1
gene, located at 20q12-q13.1, is frequently detected at elevated copy numbers in colorectal …
gene, located at 20q12-q13.1, is frequently detected at elevated copy numbers in colorectal …
Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer
SB Nygård, IJ Christensen, SL Nielsen… - Scandinavian journal …, 2013 - Taylor & Francis
Objective. DNA topoisomerase I is a putative biomarker of irinotecan efficacy with clinical
associations previously demonstrated at the protein level. The purpose of the present study …
associations previously demonstrated at the protein level. The purpose of the present study …
[HTML][HTML] Topoisomerase 1 (TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis
MU Rømer, SB Nygård, IJ Christensen, SL Nielsen… - Molecular …, 2013 - Elsevier
PURPOSE: A Topoisomerase 1 (Top1) poison is frequently included in the treatment regimens
for metastatic colorectal cancer (mCRC). However, no predictive biomarkers for Top1 …
for metastatic colorectal cancer (mCRC). However, no predictive biomarkers for Top1 …